Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011

Date: July 1, 2011
Pages: 43
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V36C82D57CFEN
Leaflet:

Download PDF Leaflet

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections therapeutic pipeline. This report provides information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections. 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Vancomycin-Resistant Enterococcus Faecium Infections.
  • A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Vancomycin-Resistant Enterococcus Faecium Infections therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Enterococcus Faecium Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Products under Development by Companies
Companies Involved in Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics Development
Achillion Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Oragenics, Inc.
Piramal Life Sciences Limited
MerLion Pharmaceuticals Pte Ltd
MicuRx Pharmaceuticals, Inc.
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACH-702 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
LOR-220 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Omadacycline - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Drug for Bacterial Infections - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MU1140 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lipopetide Program - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
PM181104 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Lipopeptide Program - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MRX-I - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MRX-II - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SLP0905 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
SLP0904 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Drug Profile Updates
Vancomycin-Resistant Enterococcus Faecium Infections - Featured News
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 43

LIST OF TABLES

Number of Products Under Development for Vancomycin-Resistant Enterococcus Faecium Infections, Q3 2011
Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Achillion Pharmaceuticals, Inc., 2011
Paratek Pharmaceuticals, Inc., 2011
Immtech Pharmaceuticals, Inc., 2011
Lorus Therapeutics Inc, 2011
Oragenics, Inc., 2011
Piramal Life Sciences Limited, 2011
MerLion Pharmaceuticals Pte Ltd, 2011
MicuRx Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics – Drug Profile Updates 40

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, Q3 2011
Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Late Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Discovery and Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011 24

Ask Your Question

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, Q3 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: